23 to 24 July 2026.
If you only want the short version. A panel of experts advised the FDA to let pharmacies start making six peptides, including BPC-157 and TB-500. They gave that advice against the recommendation of the FDA's own scientists. It is advice, not a decision, and the FDA does not have to take it. Nothing became legal on the day of the vote, and nothing has since. The earliest anyone expects that to change is well into 2027.
The rest of this page is the record of what happened, and what a vote like this has been worth historically. The second part is the reason it is worth reading, because the answer is documented and almost nobody has looked it up.
An FDA advisory committee recommended six peptides for the list of substances compounding pharmacies may use. It rejected a seventh. It did all of this against the written recommendation of the FDA's own scientists, who had reviewed all seven and advised against every one.
The record
Some orientation before the numbers, because the vote makes little sense without it.
The Pharmacy Compounding Advisory Committee, usually shortened to PCAC, is a panel that advises the FDA on what compounding pharmacies may use. Its job here was to consider whether seven peptides belong on the 503A Bulks List, which is the roster of raw ingredients a licensed pharmacy may legally make into a medicine for one named patient with a prescription. A place on that list is the only lawful route to a pharmacy-made version of most of these compounds.
Fourteen voting members. Each peptide was considered twice, once as a free base and once as an acetate, which are two chemical forms of the same substance and were voted on together in practice.1
| Peptide | Reviewed for | Vote |
|---|---|---|
| BPC-157 | Ulcerative colitis | 8 yes, 6 no, 1 abstain |
| KPV | Wound healing, inflammatory conditions | 8 yes, 6 no, 1 abstain |
| TB-500 | Wound healing | 8 yes, 6 no, 1 abstain |
| MOTS-c | Obesity, osteoporosis | 7 yes, 5 no, 2 abstain |
| Semax | Selected neurologic uses | 8 yes, 5 no, 1 abstain |
| Epitalon | Insomnia | 7 yes, 5 no, 1 abstain |
| Emideltide (DSIP) | Sleep | 6 yes, 7 no, 1 abstain. Rejected |
Two details mostly went unreported. Every peptide was nominated for a specific condition, and those conditions are narrow. BPC-157 was reviewed for ulcerative colitis, not tendons. MOTS-c for obesity and osteoporosis. If these reach the list, prescribers gain discretion well beyond what was evaluated, and the gap between the two is wider than the coverage suggests.
Emideltide is DSIP. It is the only one that failed, and almost nobody covering the vote used the name people would recognise.
How the room changed
The committee that considered these same questions in 2024 had thirteen members and said no.
By May 2026 its public roster showed three voting members of the twelve the charter requires, with the chair and the consumer representative seats vacant.4 It was reassembled before July, and one law firm described it as "hastily reassembled" in its write-up.5
The reassembly happened after a clear signal from the top. On 27 February 2026, HHS Secretary Robert F. Kennedy Jr. appeared on Joe Rogan's podcast, described himself as a big fan of peptides, said he had used them personally on injuries, and called the 2023 reclassification illegal. He predicted action within a couple of weeks.6
Six weeks later, on 15 April, the FDA removed twelve peptides from Category 2, its list of substances pharmacies must not use, and scheduled this meeting.7
The reassembled committee includes practitioners who run peptide clinics or sell peptides. The Washington Post reported conflict-of-interest concerns about the panel a week before it sat.8 HHS maintains that members passed standard ethics review and that disqualified candidates were removed.9
A smaller committee, seated under an administration that had publicly championed these compounds, is a different room from the one that voted no in 2024.
Why the FDA's own scientists said no
Before the meeting, FDA career reviewers applied the four-part legal test that governs this decision, set out at 21 CFR 216.23(c): physical and chemical characterisation, historical use in compounding, evidence of effectiveness, and safety.2
They concluded that none of the seven met the criteria. The recurring problems were inconsistent naming and missing quality data, absent human evidence, and specific safety flags. There is no human data at all for KPV, TB-500 or MOTS-c. BPC-157, emideltide and Semax had only small, poorly controlled studies.3
The committee heard that and voted the other way on six of seven.
The argument that won, and the one that lost
The case that carried the room was not that these peptides work.
It was harm reduction. Restrictions have not stopped people using these compounds; they have pushed them to an unregulated market where nobody checks identity, purity or sterility. A patient going through a licensed pharmacy gets a product with verified purity, accurate dosing, documented sterility and a prescriber's oversight. The same patient buying online gets an unmarked vial and no recourse.10
Nothing in that argument concerns evidence. It concerns what happens in the absence of a legal route, and several members found it persuasive enough to override their own agency's scientists.
The dissenting members made an argument that this page is, in a sense, proof of.
They warned that the public would read a favorable vote as an endorsement of efficacy.9 Which is precisely what happened. Headlines announced the FDA had cleared these peptides, and vendors began citing the vote as validation within days.
Some members who voted yes attached conditions: authorised API sourcing, adverse event reporting requirements, and constraints on formulation.11 Those conditions are not part of the recommendation the FDA received, and whether any of them survive into a rule is an open question.
Outside the room, PhRMA, the Partnership for Safe Medicines and the American Pharmacists Association all opposed inclusion of every one of the seven. One of their arguments stands out: Chinese manufacturers of fentanyl precursors have been pivoting into peptide sales.12
What a favorable vote has been worth
Here is the part that changes how you should read all of it.
The list this vote feeds contains six substances. Not six peptides. Six substances in total, written into federal regulation at 21 CFR 216.23(a), beginning with a laboratory dye called Brilliant Blue G.13
Hundreds of substances have been nominated for that list since 2015. Roughly ten have completed the process.14
That list was established by final rule in February 2019.21
In September 2019, the FDA published a proposed rule to add five more substances to it. That proposed rule has never been finalised. Seven years later, those five substances are still waiting.22
And there is a closer parallel. On 8 June 2022, this same committee voted 8 to 5 with one abstention to recommend glutathione for the same list, against the FDA staff recommendation. Almost exactly the margin BPC-157 just received.23
Glutathione is not on the list. Four years on.
The year before that, the committee did the same thing for methylcobalamin, also against staff. Also not on the list.23
None of which means the July vote counts for nothing. It is the most favorable regulatory signal peptides have had, and the direction of travel is real. What the record tells you about is speed, and on this particular list a favorable vote has never been sufficient on any predictable timeline.
What the timeline actually looks like
The FDA has set no deadline. The estimates from people who do this professionally cluster in a range.
Eight to twelve months at minimum before 503A pharmacies have unambiguous legal authority, according to two separate analyses.15 Six to eighteen months, according to another.16 Well into 2027 or 2028, according to a fourth.17
The steps are fixed regardless of the estimate, and the process has a name worth knowing: notice-and-comment rulemaking. The FDA decides whether to accept the recommendations. If it does, it publishes a proposed rule. The public gets a set period to comment on it. The agency considers those comments and publishes a final rule. Only that last step changes what a pharmacy may do.
One thing could compress that. A provision of the law, section 503A(c), gives the Health Secretary authority to bypass the standard advisory committee step in specific circumstances, and Kennedy has publicly championed access. No such action has been announced.18
The three events people keep merging
Much of the confusion around this comes from treating three separate things as one.
Removal from Category 2, which happened on 23 April 2026. Category 2 is the FDA's do-not-use list, and coming off it lifted that specific prohibition. It did not place anything in Category 1, and it did not authorise compounding. One law firm was explicit about it a week later: removing a Category 2 substance "does not, on its own, authorize use of that substance in compounding or bring it within FDA's interim enforcement discretion policy for substances in Category 1."19
The PCAC recommendation, which happened on 23 and 24 July. Advice to the FDA. Not an agency action.
Placement on the 503A Bulks List, which requires the rulemaking described above and has not happened.
Only the third changes what a pharmacy may legally do. The vote cleared the second.
There is one live question underneath this. Some analysts expect the FDA to signal interim enforcement discretion for the six recommended peptides while rulemaking proceeds, and the Secretary could place them in Category 1, meaning under evaluation and tolerated in the meantime, on an interim basis.11 Nothing of the sort has been announced. Reputable compounding pharmacies are not treating the vote as authorisation.20
Anyone told by a seller that these are now legal to compound is being told something the record does not support.
Who is next
The committee is scheduled to meet again before the end of February 2027, to consider five more peptides.11
GHK-Cu. Dihexa. LL-37. PEG-MGF. Melanotan II.
The list is more interesting than it looks. GHK-Cu is one of the fastest-growing compounds in this category by search volume. Melanotan II is warned against by multiple national regulators. LL-37 and PEG-MGF have essentially no human evidence at all.
Whatever happens in February, the same arithmetic applies. A favorable vote starts a process. It does not end one.
Common questions
Did the FDA approve BPC-157?
No. An advisory committee recommended it for the list of substances compounding pharmacies may use. That is advice to the FDA, not an approval and not an agency decision.
Is BPC-157 legal now?
No. Nothing changed on the day of the vote. Adding a substance to the 503A bulks list requires rulemaking that has not happened.
What did the committee actually vote on?
Whether seven peptides belong on the 503A bulks list, each for a specific named condition. BPC-157 was reviewed for ulcerative colitis, not for tendon injuries.
Which peptide was rejected?
Emideltide, which is DSIP, on a vote of 6 yes to 7 no with one abstention.
Why did the panel vote against the FDA's own scientists?
The argument that carried was harm reduction rather than efficacy: that restrictions have pushed people toward an unregulated market instead of stopping use.
How long until pharmacies can compound these?
Estimates from legal analysts range from eight to twelve months at minimum to well into 2027 or 2028. The FDA has set no deadline.
Has a committee recommendation ever failed to reach the list?
Yes. Glutathione was recommended in 2022 by 8 to 5 with one abstention, the same margin BPC-157 received, and it is still not on the list four years later. Methylcobalamin followed the same path in 2021.
What changed for you
Nothing, today.
No peptide became legal to compound on 24 July. None became an approved drug. No pharmacy that was refusing to prepare BPC-157 on 22 July has a legal basis to start.
What did change is the direction of the argument, and the position of the record. Six recommendations against the advice of the agency's own scientists is a real event, and it will be cited for years. It is also, on the evidence of the last seven years, the beginning of something that may take several more.
Sources
- FDA. Meeting of the Pharmacy Compounding Advisory Committee, 23-24 July 2026. Regulatory. Agenda and the reviewed uses for each substance.
- FDA. Briefing document, Pharmacy Compounding Advisory Committee, 2026. Regulatory. The four evaluation criteria established by the February 2019 final rule.
- Orrick. FDA peptide compounding vote: what to watch at the July PCAC meeting, July 2026. Legal analysis of the FDA briefing documents. No human data for KPV, TB-500 or MOTS-c; small, poorly controlled studies for the others. Docket FDA-2025-N-6895 drew approximately 1,860 comments.
- FDA. Pharmacy Compounding Advisory Committee roster, as archived May 2026. Regulatory. As of May 2026 the roster showed three voting members of the twelve the charter requires, with the chair and consumer representative seats vacant. The current roster has changed; the archived snapshot is the record of the claim.
- Mintz. FDA's advisory committee votes on peptides: what it does and doesn't do, July 2026. Legal analysis. Describes the committee as hastily reassembled.
- The Joe Rogan Experience, episode 2461, 27 February 2026. Interview with HHS Secretary Robert F. Kennedy Jr. Primary source. Kennedy described himself as a big fan of peptides, said he had used them on injuries, and called the 2023 reclassification illegal.
- LumaLex Law. The July 2026 PCAC peptide meeting, July 2026. Legal analysis. FDA announced on 15 April 2026, with a Federal Register notice on 16 April, that twelve peptides would come off Category 2 effective 23 April.
- Roubein R. FDA raised conflict of interest concerns ahead of new peptide panel. Washington Post, 17 July 2026. Reporting. FDA officials expressed concern about appointing members who worked for peptide-related businesses and clinics.
- FDA panel votes to loosen restrictions for four peptides, Pharmaceutical Executive, 2026. Trade reporting. Panel justification emphasised harm reduction and access; dissenters warned the public may misinterpret a favorable vote as an efficacy endorsement. HHS maintained members passed ethics review.
- What the FDA's PCAC vote means for the future of peptides, 2026. Industry analysis. Sets out the harm-reduction argument as presented to the committee.
- McDermott Will & Emery. Bulk-list bound? PCAC backs majority of peptides, July 2026. Legal analysis. Notes members conditioning recommendations on API sourcing, adverse-event reporting and formulation safeguards, and that the Secretary may add peptides to Category 1 on an interim basis.
- Same as reference 3. PhRMA, the Partnership for Safe Medicines and the American Pharmacists Association each opposed inclusion of all seven, citing conflicts of interest, absent human evidence, enforcement capacity, and Chinese fentanyl-precursor manufacturers pivoting into peptide sales.
- eCFR. 21 CFR 216.23. The codified list. Six substances.
- Same as reference 7. Of the hundreds of substances nominated over the years, roughly ten have completed the process.
- ArentFox Schiff. The (Pep)Tides Turn: FDA panel recommends six of seven for compounding, 31 July 2026, and reference 5. Legal analyses. Both give eight to twelve months at minimum for unambiguous legal authority.
- July 2026 peptide FDA decision: what it actually means, 2026. Six to eighteen months.
- Sheppard Mullin. Compounded peptides on the loose, 2026. Legal analysis. Rulemaking could extend well into 2027 or 2028.
- FDA PCAC peptide compounding review July 2026, June 2026. Notes that section 503A(c) provides the Secretary authority to bypass standard advisory committee consultation in specific circumstances, and that no such action has been announced.
- Polsinelli, quoted in reference 4, 22 April 2026. States that removing a Category 2 substance does not on its own authorise compounding or bring it within the Category 1 enforcement discretion policy.
- Same as reference 10. Reputable compounding pharmacies are unlikely to treat the vote as authorisation.
- FDA. List of bulk drug substances that can be used to compound drug products under section 503A, Federal Register, 19 February 2019, 84 FR 4696. Final rule. Placed six substances on the list and established the four evaluation criteria.
- FDA. Bulk drug substances used in compounding under section 503A. Agency page. Confirms the September 2019 proposed rule to add five substances, and that no final rule has followed.
- Alliance for Pharmacy Compounding. PCAC recommends glutathione for bulks list, June 2022. Trade reporting. 8-5 with one abstention, against FDA staff, and the same pattern with methylcobalamin the previous year.